Summary
The response set provided includes many claims about lisinopril/Zestril indications, dosing, switching, and adverse effects, but only fetal toxicity/pregnancy content is supported by the supplied label excerpts. Claims outside the provided fetal toxicity/pregnancy sections are therefore unsupported for this audit, and at least one claim is materially incomplete/unsafe relative to the supplied label focus (pregnancy management details).
Category Scores
Accurate Statements
Zestril (lisinopril) can cause fetal harm when administered to a pregnant woman, with fetal/neonatal adverse reactions including oligohydramnios and outcomes such as hypotension, renal failure, and death; drugs acting on the renin-angiotensin system during the second/third trimesters increase morbidity and death; discontinue Zestril as soon as possible when pregnancy is detected; closely observe exposed infants and support BP/renal perfusion if needed.
Supported by supplied label text in 5.1 Fetal Toxicity and 8.1 Pregnancy.
Unsupported Statements
Lisinopril is used for conditions such as high blood pressure.
The supplied label excerpts only cover fetal toxicity/pregnancy and do not include indications.
Lisinopril is used for heart-related problems.
The supplied label excerpts only cover fetal toxicity/pregnancy and do not include indications.
A “Zestril generic” is a generic version of lisinopril made by other manufacturers.
The supplied label excerpts do not address generic drug manufacturing/definitions.
Zestril generics use the same active ingredient, lisinopril.
The supplied label excerpts do not discuss generic interchangeability/active ingredient equivalence.
Generic medicines are designed to be interchangeable with the brand version because they use the same active ingredient and meet regulatory requirements for quality, strength, and performance.
The supplied label excerpts do not discuss FDA generic interchangeability requirements.
In practice, pill appearance and inactive ingredients can differ between brand and generic versions of lisinopril.
The supplied label excerpts do not discuss inactive ingredients or appearance differences.
The drug effect comes from lisinopril.
The supplied label excerpts do not state that effect is due solely to lisinopril.
The active ingredient name for Zestril generic products is lisinopril.
The supplied label excerpts do not discuss generic product labeling.
Some generic products may list lisinopril dihydrate as formulation wording.
The supplied label excerpts do not discuss lisinopril dihydrate wording.
Generic selection for lisinopril commonly involves comparing dose strength.
The supplied label excerpts do not discuss how to select generics.
Lisinopril is commonly taken once daily.
The supplied label excerpts do not provide dosing frequency.
Immediate-release is typical for lisinopril.
The supplied label excerpts do not provide formulation/IR statements.
Some places may automatically substitute generic medicines unless “dispense as written” is requested.
The supplied label excerpts do not address pharmacy substitution laws/policies.
Most people can switch between Zestril and generic lisinopril without issue.
The supplied label excerpts do not address switching outcomes.
Switching concerns may apply for people who have had side effects or blood pressure instability with a prior switch.
The supplied label excerpts do not address switching concerns.
Switching concerns may apply for people taking multiple blood-pressure or heart medicines.
The supplied label excerpts do not address switching concerns or polypharmacy.
People with kidney disease or potassium issues require important monitoring for lisinopril.
The supplied label excerpts only mention neonatal hyperkalemia monitoring; they do not discuss adult kidney disease/potassium monitoring.
Lisinopril can cause dizziness or low blood pressure.
The supplied label excerpts do not state these adverse events for general use (they mention hypotension in neonates only).
Lisinopril can cause cough.
The supplied label excerpts do not list cough as an adverse reaction.
Lisinopril can cause lab changes such as elevated potassium.
The supplied label excerpts only support hyperkalemia monitoring in infants with in utero exposure; they do not broadly state elevated potassium as an adverse reaction.
Lisinopril can cause swelling (angioedema).
The supplied label excerpts do not mention angioedema.
Lisinopril can cause kidney function changes.
The supplied label excerpts support reduced fetal renal function/anuria/renal failure in neonates; they do not broadly support adult kidney function changes.
If a prescription is for “Zestril,” a prescriber may write for “lisinopril” (or “lisinopril equivalent”) if appropriate.
The supplied label excerpts do not include prescribing/substitution wording guidance.
Pharmacists can often substitute generics, depending on the prescription wording and local rules.
The supplied label excerpts do not address pharmacists/substitution rules.
To confirm what you’ll get, you can check the prescription label or bottle for active ingredient lisinopril.
The supplied label excerpts do not provide instructions for confirming what to receive.
To confirm what you’ll get, you can check the prescription label or bottle for strength that matches your dose.
The supplied label excerpts do not provide instructions for dose strength matching.
To confirm what you’ll get, you can check the prescription label or bottle for instructions that match your regimen.
The supplied label excerpts do not provide instructions for matching regimen instructions.
Contradictions
Important Omissions
The response set includes many general safety/clinical claims, but does not emphasize/explicitly align with the provided label directive: when pregnancy is detected, discontinue Zestril as soon as possible, and closely observe infants for hypotension, oliguria, and hyperkalemia with potential need for support/dialysis/exchange transfusion as described.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because most claims are unsupported by the supplied fetal toxicity/pregnancy label excerpts, the response may mislead readers about indications, dosing, switching, and general adverse effects. Additionally, pregnancy management details are not clearly and exclusively represented, increasing risk of unsafe reliance on incomplete on-label information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Only fetal toxicity/pregnancy statements are supported by the provided label text; the majority of other claims are unsupported given the limited label excerpts supplied.
Suggested Improvement
Restrict claims to the supplied on-label pregnancy/fetal toxicity content (Zestril fetal harm, trimester risk, discontinue as soon as possible when pregnancy is detected, infant monitoring and possible supportive interventions). Remove or clearly qualify statements about indications, dosing, switching/interchangeability, and general adverse effects unless the corresponding FDA label sections are provided for verification.